Abstract
<h3>Purpose</h3> Endoluminal brachytherapy is an effective treatment modality for endobronchial tumours. With the advent of image-guidance, target coverage has improved and volume-based target delineation has helped in conformal treatment. In this study, we report our experience with high dose rate endobronchial brachytherapy (HDR-EBBT) and to assess its efficacy and tolerability. <h3>Materials and Methods</h3> Between January 2015 to February 2022, a retrospective review of patients with endobronchial tumours treated at our institution with HDR-EBBT was retrospectively assessed. Analysis of disease characteristics and thereafter, the subjective response and treatment related toxicities were extracted from patient records. The follow-up was undertaken as per the institutional protocol. Local control (LC) and overall survival (OS) were analysed. During each procedure of EBBT, a source-centralizing applicator was used which kept the source-dwelling catheter in the centre of bronchial lumen and reference dose point was placed 5 mm from source axis as per the bronchial diameter. <h3>Results</h3> With a median follow up of 18 months, a total of 8 patients with histopathologically proven endobronchial tumours were identified. The median external beam radiation dose was 45Gy in 25 fractions followed by brachytherapy dose of 14Gy in 2 fractions with treatment a week apart. The commonest symptoms to palliate included dyspnea (5/8), cough (3/8), and hemoptysis (4/8). The median disease-free survival and overall survival was 18 months and 21 months respectively. No grade 3-5 acute or late toxicities were reported and only one patient required further palliation measures to control the symptoms. On dosimetric analysis the PTV V95% and V98% were 95.12% and 93.45% respectively. On assessing the D20 and D5 for lungs, the median dose was 1.32Gy and 0.73Gy respectively. Similarly, the D2cc, 1cc and 0.1cc of oesophagus and heart were 1.63, 1.89 and 2.67Gy and 1.15, 1.37 and 1.69Gy respectively. <h3>Conclusion</h3> HDR-EBBT is a promising treatment with minimal complications and improved outcomes and thus provide curative options. If performed properly, desirable dosimetry can be achieved to improve target coverage and reduced normal tissue doses.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.